The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Trial in progress: RASolute 302—A phase 3, multicenter, global, open-label, randomized study of daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor, versus standard of care chemotherapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).
 
Brian Wolpin
Consulting or Advisory Role - Agenus; EcoR1 Capital; Harbinger Health; Ipsen; Mirati Therapeutics; Revolution Medicines; Tango Therapeutics; Third Rock Ventures
Research Funding - Agios; Amgen; Amgen; AstraZeneca (Inst); Harbinger Health (Inst); Lilly (Inst); Novartis (Inst); Revolution Medicines (Inst)
 
Zev Wainberg
Consulting or Advisory Role - Alligator Bioscience; Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; EMD Serono; Ipsen; Janssen Oncology; Lilly; Merck; Merck KGaA; Novartis; Pfizer; PureTech; Revolution Medicines; Seagen
Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Lilly; Merck
 
Ignacio Garrido-Laguna
Consulting or Advisory Role - Abbvie; Lilly; Quanta Therapeutics; Revolution Medicines; SOTIO
Research Funding - 280 BIO (Inst); ABM (Inst); Bayer (Inst); BridgeBio Pharma (Inst); Bristol-Myers Squibb (Inst); EcoR1 Capital; GlaxoSmithKline (Inst); Guidepoint Inc; Incyte (Inst); Jacobio (Inst); Lilly (Inst); MedImmune (Inst); Novartis (Inst); Pfizer (Inst); Quanta Therapeutics (Inst); Repare Therapeutics (Inst); Revolution Medicines (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Tango Therapeutics (Inst); Tolero Pharmaceuticals (Inst); Yingli Pharma (Inst)
 
Gulam Manji
Stock and Other Ownership Interests - EnGeneIC
Honoraria - Celgene; Exelixis; Roche/Genentech
Consulting or Advisory Role - Cend Therapeutics; EnGeneIC; Exelixis; Ipsen; Pfizer; Revolution Medicines; Roche/Genentech
Research Funding - Arcus Biosciences; BiolineRx (Inst); Merck (Inst); Plexxikon (Inst); Regeneron (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Celgene; DAVA Oncology; Exelixis; Revolution Medicines; Roche/Genentech
 
Alexander Spira
Leadership - Next Oncology (Inst)
Honoraria - Abbvie; Abbvie; Abbvie; Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Prelude Therapeutics; Takeda
Consulting or Advisory Role - Amgen; ArriVent Biopharma; AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Sanofi; Sanofi; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst)
 
Nilofer Azad
Stock and Other Ownership Interests - Cage Pharma; Irazu; Tempus
Consulting or Advisory Role - Agenus; Astellas Pharma; AstraZeneca; BeiGene; GlaxoSmithKline; Incyte; Jazz Pharmaceuticals; Jazz Pharmaceuticals; Lilly; Mirati Therapeutics; Taiho Pharmaceutical; Tempus
Research Funding - Agios (Inst); Array BioPharma (Inst); Astex Pharmaceuticals (Inst); AtlasMedx (Inst); Bayer (Inst); BeiGene (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Debiopharm Group (Inst); EMD Serono (Inst); Genentech (Inst); Incyte (Inst); Intensity Therapeutics (Inst); Loxo/Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Revolution Medicines (Inst); Syndax (Inst)
Travel, Accommodations, Expenses - Mirati Therapeutics
 
Shubham Pant
Stock and Other Ownership Interests - Teleprian
Consulting or Advisory Role - Alligator Bioscience; Arcus Biosciences; AskGene Pharma; AstraZeneca; Boehringer Ingelheim; BPGbio; Ipsen; Janssen; Jazz Pharmaceuticals; Merck; Nihon Medi-Physics; Novartis; Pfizer; Revolution Medicines; US WorldMeds
Research Funding - 4D Pharma (Inst); Amal Therapeutics (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); bionte (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Elicio Therapeutics (Inst); Immuneering (Inst); ImmunoMET (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); Mirati Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Purple Biotech (Inst); Rgenix (Inst); Xencor (Inst); Zymeworks (Inst)
 
Ying Zhang
Employment - Revolution Medicines
Stock and Other Ownership Interests - Revolution Medicines
 
Jessica Trang
Employment - Revolution Medicines
Stock and Other Ownership Interests - Revolution Medicines
 
Zeena Salman
Employment - Revolution Medicines
Stock and Other Ownership Interests - Revolution Medicines
 
Eileen O'Reilly
Consulting or Advisory Role - Abbvie (I); AstraZeneca; Autem Medical (I); Berry Genomics (I); BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Eisai (I); Exelixis (I); Genentech/Roche (I); Ipsen; J-Pharma (I); Merck; Merus; Novartis; QED Therapeutics (I); Revolution Medicines; SERVIER (I); Vector Health (I); Yiviva (I)
Research Funding - Agenus (Inst); Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Bristol Myers Squibb (Inst); Digestive Care (Inst); Elicio Therapeutics (Inst); Genentech (Inst); Helsinn Healthcare (Inst); Parker Institute for Cancer Immunotherapy (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Revolution Medicines (Inst); Yiviva (Inst)
(OPTIONAL) Uncompensated Relationships - Thetis Pharma